Value in Health

Published by: Elsevier Science, Inc.  

People

  1. Shah
    Shah
  2. Mauro
    Mauro
  3. Stein
    Stein
  4. Kung
    Kung
  5. Geyer
    Geyer
  6. Giralt
    Giralt
  7. Palomba
    Palomba
  8. Park
    Park
  9. Perales
    Perales
  10. Price
    Price

Groups

  1. Center for Hematologic Malignancies (20)
  2. Department of Medicine (17)
  3. Hematologic Malignancies, Division of (17)
  4. Adult Leukemia (13)
  5. Bone Marrow Transplant (4)
  6. Survivorship Research (4)
  7. Executive Committee, Center for Hematologic Malignancies (3)
  8. Hematologic Malignancies Research (2)
  9. Myeloma (2)
  10. Pediatrics, Department of (2)
Search Within
  1. "Center for Hematologic Malignancies"
Formats
  1. Meeting Abstract (18)
  2. Journal Article (2)
Groups
  1. Center for Hematologic Malignancies (20)
  2. Department of Medicine (17)
  3. Hematologic Malignancies, Division of (17)
  4. Adult Leukemia (13)
  5. Bone Marrow Transplant (4)
  6. Survivorship Research (4)

More Groups

People
  1. Eytan Stein (4)
  2. Gunjan Shah (4)
  3. Anthony Mato (3)
  4. Michael Mauro (3)
  5. Andrew Kung (2)
  6. Martin Tallman (2)

More People

Years
  1. 2023 (1)
  2. 2022 (3)
  3. 2020 (3)
  4. 2019 (2)
  5. 2018 (2)
  6. 2017 (5)

More Years

Publishers
  1. Elsevier Science, Inc. (20)

Results (20)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world treatment patterns, healthcare resource utilization (HRU) and costs for relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Chimeric antigen receptor T-cell (CAR T) and monoclonal antibodies (MAB) therapies
    Meeting Abstract

    Feng, C.; Murphy, L.; Engel-Nitz, N.; Nguyen, A.; Patel, A.; DuCharme, M.; Fu, C.; Shah, G.
    Value in Health (2023)

    Fulltext@MSK | Save
  • Health care resource utilization with asciminib and bosutinib among adults with chronic myeloid leukemia in chronic phase previously treated with ≥2 tyrosine kinase inhibitors: Week 48 and week 96 results from ASCEMBL trial
    Meeting Abstract

    Cortes, J. E.; Sasaki, K.; Réa, D.; Mauro, M. J.; Tran, D.; Wang, P.; Jadhav, K.; Di Caprio, L.; Yocolly, A.
    Value in Health (2022)

    Fulltext@MSK | Save
  • A matching-adjusted indirect comparison of asciminib versus ponatinib, nilotinib and dasatinib in chronic phase chronic myeloid leukemia patients after ≥2 tyrosine kinase inhibitors
    Meeting Abstract

    Atallah, E. L.; Maheshwari, V.; Mauro, M. J.; Boquimpani, C.; Rea, D.; Hochhaus, A.; Minami, Y.; Saini, L.; Corbin, R.
    Value in Health (2022)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) from the informCLL registry: A prospective, multicenter, observational study of US patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Cll/Sll)
    Meeting Abstract

    Sharman, J.; Barrientos, J. C.; Ghosh, N.; Brander, D.; Gutierrez, M.; Wu, L.; Panjabi, S.; Upasani, S.; Jermain, M.; Naganuma, M.; more...
    Value in Health (2022)

    Fulltext@MSK | Save
  • Real-world healthcare resource utilization and total cost of care among US Medicare patients with chronic lymphocytic leukemia receiving first-line ibrutinib vs chemoimmunotherapy
    Meeting Abstract

    Huang, Q.; Emond, B.; Lafeuille, M. H.; Gupta, D.; Lefebvre, P.; Sundaram, M.; Mato, A.
    Value in Health (2020)

    Fulltext@MSK | Save
  • Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: A SEER-Medicare analysis
    Meeting Abstract

    Stein, E. M.; Latremouille-Viau, D.; Shi, S.; Guerin, A.; Wu, E.; Bonifacio, G.; Cao, X.
    Value in Health (2020)

    Fulltext@MSK | Save
  • Critical appraisal of published indirect comparisons and network meta-analyses of competing interventions for multiple myeloma
    Journal Article

    Cope, S.; Toor, K.; Popoff, E.; Fonseca, R.; Landgren, O.; Mateos, M. V.; Weisel, K.; Jansen, J. P.
    Value in Health (2020)

    Fulltext@MSK | Save
  • Cost-effectiveness of a 24-month fixed duration of venetoclax in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia in the United States
    Meeting Abstract

    Huntington, S. F.; Strunz-McKendry, T.; Masaquel, A. S.; Shapouri, S.; Sail, K.; Durno, N.; Mato, A.
    Value in Health (2019)

    Fulltext@MSK | Save
  • Resource utilization within 30 days of car T cells for hematologic malignancies
    Meeting Abstract

    Shah, G.; Park, J.; Sauter, C.; Duck, E.; Halton, E.; Batlevi, C.; Palomba, M. L.; Younes, A.; Geyer, M.; Smith, E.; more...
    Value in Health (2019)

    Fulltext@MSK | Save
  • Expanded genomic testing for pediatric cancers is clinically impactful but reimbursement lags behind
    Meeting Abstract

    Oberg, J. A.; Sireci, A. N.; Hsiao, S. J.; Pendrick, D.; Turk, A. T.; Chung, W. K.; Sulis, M. L.; Kung, A. L.; Mansukhani, M. M.; Bender, J. L. G.
    Value in Health (2018)

    Fulltext@MSK | Save

    • Value in Health – authorized name for:

    Name ISSN / ISBN Publisher
    Value in Health 10983015 International Society for Pharmacoeconomics and Outcomes Research (ispor)
    Value in Health 10983015 International Society for Pharmacoeconomics and Outcomes Research, Inc
    Value in Health 1098-3015 Elsevier Science, Inc.
    Value in Health 10983015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
    Value in Health 1098-3015 Unknown
    Value in Health 1098-3015 Elsevier Science, Inc.
    Value in Health 1098-3015 Elsevier B.V.
    Value in Health 10983015 2023
    Value in Health 10983015 Ispor–the Professional Society for Health Economics and Outcomes Research
    Value in Health 1098-3015 Blackwell Publishing
    Value in Health 1098-3015 Elsevier Science, Inc.
    Value in Health 1098-3015 Elsevier B.V.
    Value in Health 1098-3015 Elsevier Science, Inc.
    Value in Health 10983015 Unknown